By Bill Berkrot ORLANDO (Reuters) – The Novo Nordisk diabetes drug Victoza failed to improve clinical stability or delay death in patients suffering from advanced heart failure, researchers reported at a medical meeting on Sunday. The injectable drug, known chemically as liraglutide, was tested in 300 patients with and without type 2 diabetes who had advanced heart failure and a recent hospitalization. Researchers had hoped that the medicine’s effect on blood sugar could mitigate some of the metabolic effects of heart failure.
Original post:
Novo Nordisk diabetes drug fails to help heart failure: study
